← Back to Patent Explorer
US5486359A Expired / Lapsed US ⏱️ 0.0 years remaining

Human mesenchymal stem cells

Assignee: Mesoblast International SARL
•
Filing: 1994-02-08
•
Granted: 1996-01-23
•
Expires: 2014-02-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Isolated human mesenchymal stem cells which can differentiate into more than one tissue type (e.g. bone, cartilage, muscle or marrow stroma), a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. "mesenchymal stem cells" or "hMSCs"), and characterization of and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.

Inventors

  • 👤 Arnold I. Caplan
  • 👤 Stephen E. Haynesworth

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:01
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/3834; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61L27/3839; A61L27/3843; A61L31/00; A61L31/005; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C12; C12N; C12N5/00; C12N5/0068; C12N5/06; C12N5/0602; C12N5/0652; C12N5/0662; C12N5/0663; A61F2/30; A61F2/30756; A61K2035/124; A61L2430/00; A61L2430/10; C12N2501/00; C12N2501/20; C12N2501/23; C12N2501/30; C12N2501/38; C12N2501/39; C12N2533/00; C12N2533/10; C12N2533/18

Claims Analysis

Total Claims: 39
Claim 1
Independent Claim 21 words
An isolated, homogeneous population of human mesenchymal stem cells which can differentiate into cells of more than one connective tissue type.
Claim 2
Dependent Claim 21 words
An isolated, homogeneous population of human mesenchymal stem cells which can differentiate into cells of more than one connective tissue type.
Claim 3
Dependent Claim 27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH2, ATCC accession number HB 10743, binds to said mesenchymal stem cells.
Claim 4
Dependent Claim 17 words
The mesenchymal stem cells of claim 2 wherein said mesenchymal stem cells are obtained from bone marrow.
Claim 5
Dependent Claim 27 words
The mesenchymal stem cells of claim 3 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 6
Dependent Claim 29 words
The mesenchymal stem cells of claim 3 wherein said mesenchymal stem cells retain the potential to differentiate into more than one connective tissue type after population expansion in culture.
Claim 7
Dependent Claim 27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH3, ATCC accession number HB 10744, binds to said mesenchymal stem cells.
Claim 8
Dependent Claim 27 words
The mesenchymal stem cells of claim 1 wherein an antibody produced from hybridoma cell line SH4, ATCC accession number HB 10745, binds to said mesenchymal stem cells.
Claim 9
Dependent Claim 17 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are obtained from bone marrow.
Claim 10
Dependent Claim 27 words
The mesenchymal stem cells of claim 8 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 11
Dependent Claim 15 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are non-embryonic cells.
Claim 12
Dependent Claim 27 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells adhere to a plastic surface when cultured in BGJ b medium containing 10% fetal serum.
Claim 13
Dependent Claim 29 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells retain the potential to differentiate into more than one connective tissue type after population expansion in culture.
Claim 14
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein said mesenchymal stem cells are obtained from periosteum.
Claim 15
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is bone.
Claim 16
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is cartilage.
Claim 17
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is adipose.
Claim 18
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is tendon.
Claim 19
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is ligament.
Claim 20
Dependent Claim 16 words
The mesenchymal stem cells of claim 1 wherein one of said connective tissue types is dermis.
Claim 21
Dependent Claim 23 words
A composition comprising the mesenchymal stem cells of claim 1 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 22
Dependent Claim 12 words
The composition of claim 20 wherein said medium is a complete medium.
Claim 23
Dependent Claim 12 words
The composition of claim 21 wherein said medium comprises BGJ b medium.
Claim 24
Dependent Claim 23 words
A composition comprising the mesenchymal stem cells of claim 2 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 25
Dependent Claim 12 words
The composition of claim 23 wherein said medium is a complete medium.
Claim 26
Dependent Claim 12 words
The composition of claim 24 wherein said medium comprises BGJ b medium.
Claim 27
Dependent Claim 23 words
A composition comprising the mesenchymal stem cells of claim 8 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 28
Dependent Claim 12 words
The composition of claim 26 wherein said medium is a complete medium.
Claim 29
Dependent Claim 12 words
The composition of claim 27 wherein said medium comprises BGJ b medium.
Claim 30
Dependent Claim 23 words
A composition comprising the mesenchymal stem cells of claim 5 and a culture medium, wherein said culture medium expands said mesenchymal stem cells.
Claim 31
Dependent Claim 12 words
The composition of claim 29 wherein said medium is a complete medium.
Claim 32
Dependent Claim 12 words
The composition of claim 30 wherein said medium comprises BGJ b medium.
Claim 33
Dependent Claim 32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 1 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 34
Dependent Claim 32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 2 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 35
Dependent Claim 32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 8 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 36
Dependent Claim 32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 9 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 37
Dependent Claim 32 words
A therapeutic composition comprising the mesenchymal stem cells of claim 11 and a pharmaceutically acceptable carrier, wherein said mesenchymal stem cells are present in an amount effective to produce connective tissue cells.
Claim 38
Dependent Claim 12 words
The therapeutic composition of claim 32 wherein said connective tissue is bone.
Claim 39
Dependent Claim 12 words
The therapeutic composition of claim 32 wherein said connective tissue is cartilage.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-01-22 1999-07-24 2000-01-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-01-22 2003-07-24 2004-01-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-01-22 2007-07-24 2008-01-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag